2020 Figure's:
🇬🇧 70% sales NHS/DHSC
👨💼 18% via Distributors (UK & International)
🔬 12% Private Lab sales
#Novacyt #ALNOV #NCYT
10 COVID products launched
ProMATE simplifies sample preparation, to be applied to:
Infectious diseases
Respiratory
Transplant
"targeted niches where we believe there is still very high unmet medical need"
"faster, more accurate or easier diagnosis" #Novacyt #ALNOV #NCYT
Risks:
"Management's confidence in settling the outstanding commercial dispute"
If dispute isn't favourably resolved #Novacyt has sufficient cash untill June 2022 without need to raise finding
#ALNOV #NCYT
#Novacyt #ALNOV #NCYT
DHSC Dispute £129m, with additional £49m of delivered good not paid for
£19.7m set aside in event DHSC warranty claim is successful
It is "possible, but not probable, that the refund claim" will be successful. Settlement amount may differ
investormeetcompany.com/investor/meeti…
Q1 #Novacyt "reiterating the £100 million revenue guidance for the full year, excluding DHSC, and we’re feeling confident about that number"
"see a growing private testing market & we also expect overall demand to increase as we head into the winter"
Q2 - "Unfortunately, we have no update on the dispute with the DHSC regarding the second supply contract, with no further news since the disclosure in June this year. Both sides are bound by confidentiality clause of the contract" #Novacyt #ALNOV
AGM Resolution 6.
Company seeks approval for facility to buy back up to 10% of company shares up to a value of €12
2020 Clause limiting buy back to max of €200k has been removed
#Novacyt #ALNOV
Q6 -
2021 1st H Distributors, represented approximately 35% of business (ex DHSE contract)
Americas (inc Latin America) approx 30%
Europe, Middle East & Africa, approx 55% (25% is UK & Ireland)
Asia 15%
Direct sales generated 65% of revenues (ex DHSC)
Q7 - Home LFT
"well progressed in the discussions on that second self testing application"
Global regulatory applications ✅
"bit too soon after launch to give any specific sales data but as far as the UK is concerned"
🇬🇧 free LFT's impacting sales for now #Novacyt #ALNOV
Q10 & 11
"Dual listing strategy makes sense for the company today"
🇺🇲 expansion "in the process of developing our plans as we speak and hopefully, in the near future, we will update all shareholders with those plans"
#Novacyt #ALNOV
Main growth driver, decentralised Point of Care solution
Leveraging q16/32's with ProMATE
#Novacyt #ALNOV
Targeting meaningful, high margin neiche markets
#Novacyt's best-in-class products, significant global sales & growing brand with strong balance sheet
"support the company's growth trajectory as we continue to deliver against our stated strategy"
#Novacyt #ALNOV
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.